Skip to main content

Revvity stock price and financials

  • RVTY · NYSE
  • Instruments
  • Health Care Equipment
  • S&P 500
$154.39−1.67%Close 13 Nov 2026
EV / EBITDA
24.71
Beta · 1 year
1.15
Return · 1 year
+64.0%
52-week range$81.22 — $171.74

Share price close 16 Nov 2026

−2.8%1 monthHigh $165.78Low $150.39
$150$155$160$165$170Q3 FY2026 report filed 10 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
+60.0%6 monthsHigh $165.78Low $94.80
$80$100$120$140$160$180Q2 FY2026 report filed 11 Aug 2026Q3 FY2026 report filed 10 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+55.4%year to dateHigh $165.78Low $82.26
$75$100$125$150$175Q4 FY2025 report filed 24 Feb 2026Q1 FY2026 report filed 12 May 2026Q2 FY2026 report filed 11 Aug 2026Q3 FY2026 report filed 10 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+62.2%1 yearHigh $165.78Low $82.26
$75$100$125$150$175Q4 FY2025 report filed 24 Feb 2026Q1 FY2026 report filed 12 May 2026Q2 FY2026 report filed 11 Aug 2026Q3 FY2026 report filed 10 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+68.7%3 yearsHigh $165.78Low $82.26
$75$100$125$150$175Q4 FY2023 report filed 27 Feb 2024Q1 FY2024 report filed 7 May 2024Q2 FY2024 report filed 6 Aug 2024Q3 FY2024 report filed 6 Nov 2024Q4 FY2024 report filed 25 Feb 2025Q1 FY2025 report filed 6 May 2025Q2 FY2025 report filed 5 Aug 2025Q3 FY2025 report filed 4 Nov 2025Q4 FY2025 report filed 24 Feb 2026Q1 FY2026 report filed 12 May 2026Q2 FY2026 report filed 11 Aug 2026Q3 FY2026 report filed 10 Nov 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+201%10 yearsHigh $201.06Low $50.99
$50$100$150$200$250Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Revvity reported revenue of $2.86 billion for fiscal year 2025 (the twelve months to 28 Dec 2025), up 3.7% from fiscal 2024. Net income was $241 million and diluted earnings per share $2.07.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 4 Oct 2026), revenue was $729 million, up 4.3% from a year earlier.

Figures from Revvity's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 10 Nov 2026.

Revenue FY2025
$2.86B+3.7%
Net income
$241.2M−10.8%
Diluted EPS
$2.07−5.9%
Gross margin
54.8%−1.0 pts
Free cash flow
$509.4M−6.0%
Net debt
$2.50B+14.4%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$1B$2B$3B$4BRevenue, FY16: $2.12BNet income, FY16: $234.3MFY16Revenue, FY17: $2.26BNet income, FY17: $292.63MFY17Revenue, FY18: $2.78BNet income, FY18: $237.93MFY18Revenue, FY19: $2.88BNet income, FY19: $227.56MFY19Revenue, FY20: $3.78BNet income, FY20: $727.89MFY20Revenue, FY21: $3.83BNet income, FY21: $943.16MFY21Revenue, FY22: $3.31BNet income, FY22: $569.18MFY22Revenue, FY23: $2.75BNet income, FY23: $693.09MFY23Revenue, FY24: $2.76BNet income, FY24: $270.38MFY24Revenue, FY25: $2.86BNet income, FY25: $241.2MFY25

Latest quarter · Q3 FY2026 to 4 Oct 2026, filed 10 Nov 2026 · Full results →

Revenue
$728.9M+4.3% on a year
Gross margin
57.4%+3.8 pts on a year
Operating income
$95.14M+16.2% on a year
Net income
$62.30M+33.5% on a year
Diluted EPS
$0.56+40.0% on a year
Free cash flow
$152.4M+27.0% on a year

Comparable companies All of Health Care →

Revvity beside the other S&P 500 members in Health Care Equipment, by market value.

Revvity and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
RevvityRVTY—−1.7%+64.0%———
Abbott LaboratoriesABT$188.1B+1.2%−15.8%+10.0%9.7%40.0
Intuitive SurgicalISRG$152.6B+0.8%−22.5%+20.5%25.5%51.6
Boston ScientificBSX$63.86B+0.3%−57.4%+8.9%16.6%18.2
Edwards LifesciencesEW$61.47B+1.3%+25.2%+13.4%15.3%60.2
Becton DickinsonBDX$59.14B+1.1%+44.4%−2.6%4.5%62.9
Idexx LaboratoriesIDXX$55.78B+0.9%−1.3%+11.9%25.4%47.2

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%25%50%75%54.8%12.5%8.4%FY16FY19FY22FY25

Revvity revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Revvity revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023*FY 2024FY 2025
Life Sciences$895.9M$1.29B+44.3%$1.46B$1.40B−4.1%$1.43B+2.3%
Diagnostics$2.93B$2.02B−31.1%$1.29B$1.36B+5.0%$1.42B+5.1%
Total revenue$3.83B$3.31B$2.75B$2.76B$2.86B

* The company changed how it cuts its revenue from this year; the lines before and after are not compared.

By product

Revvity revenue by product, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Product$2.74B$2.63B−3.7%$2.42B−8.3%$2.34B−3.2%$2.39B+2.2%
Service$1.09B$677.2M−38.0%$334.7M−50.6%$416.8M+24.5%$466.1M+11.8%
Total revenue$3.83B$3.31B$2.75B$2.76B$2.86B

By region

Revvity revenue by region, by fiscal year
RevenueFY 2023FY 2024FY 2025
United States$1.12B$1.10B−1.8%$1.13B+2.6%
Other International$859.9M$931.7M+8.4%$1.00B+7.4%
China$454.4M$450.0M−1.0%$425.1M−5.5%
Germany$193.2M$162.6M−15.8%$177.7M+9.3%
United Kingdom$125.4M$112.9M−10.0%$126.8M+12.4%
Total revenue$2.75B$2.76B$2.86B

Financial statements

Fiscal years, the latest ending 28 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Revvity income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$2.12B$2.26B$2.78B$2.88B$3.78B$3.83B$3.31B$2.75B$2.76B$2.86B
Revenue growth+0.5%+6.7%+23.1%+3.8%+31.2%+1.2%−13.5%−16.9%+0.2%+3.7%
Gross profit$1.01B$1.07B$1.34B$1.40B$2.11B$2.43B$1.99B$1.54B$1.54B$1.56B
Operating income$294.6M$295.6M$323.9M$362.0M$867.3M$1.26B$742.7M$300.6M$346.7M$356.6M
Net income$234.3M$292.6M$237.9M$227.6M$727.9M$943.2M$569.2M$693.1M$270.4M$241.2M
Diluted EPS$2.12$2.64$2.13$2.04$6.49$8.08$4.50$5.55$2.20$2.07
Gross margin47.9%47.6%48.3%48.4%55.8%63.6%60.1%56.0%55.8%54.8%
Operating margin13.9%13.1%11.7%12.6%22.9%32.9%22.4%10.9%12.6%12.5%
Net margin11.1%13.0%8.6%7.9%19.2%24.6%17.2%25.2%9.8%8.4%

Cash flow

Revvity cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$350.6M$288.5M$311.0M$363.5M$892.2M$1.41B$679.8M$91.27M$628.3M$582.9M
Capital expenditure$31.70M$39.09M$93.25M$76.33M$63.63M$86.02M$85.63M$81.37M$86.65M$73.52M
Free cash flow$318.9M$249.4M$217.8M$287.1M$828.5M$1.32B$594.2M$9.90M$541.7M$509.4M

Balance sheet and shares

Revvity balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$359.3M$202.1M$163.1M$191.9M$402.0M$603.3M$454.4M$913.2M$1.16B$919.9M
Total debt$1.05B$2.01B$1.89B$2.26B$2.24B$5.20B$4.63B$4.09B$3.35B$3.42B
Shareholders' equity$2.15B$2.50B$2.58B$2.81B$3.74B$7.14B$7.38B$7.87B$7.67B$7.25B
Diluted shares110M111M112M112M112M117M126M125M123M117M
Dividends per share$0.28$0.28$0.28$0.28$0.28—$0.28$0.28$0.28$0.28

Quarterly figures

The last eight fiscal quarters, the latest ending 4 Oct 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Revvity quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$729.4M$664.8M$720.3M$698.9M$772.1M$711.1M$729.7M$728.9M
Revenue, year on year+4.8%+2.3%+4.1%+2.2%+5.9%+7.0%+1.3%+4.3%
Gross margin56.5%56.5%54.5%53.6%54.6%54.5%57.1%57.4%
Operating income$118.8M$72.23M$90.76M$81.90M$111.7M$75.89M$89.32M$95.14M
Net income$94.64M$42.24M$53.95M$46.65M$98.36M$40.72M$51.82M$62.30M
Diluted EPS$0.78$0.35$0.46$0.40$0.87$0.36$0.47$0.56
Free cash flow$149.8M$112.2M$115.5M$120.0M$161.8M$95.45M$180.9M$152.4M

Operating KPIs

The operating figures Revvity reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Revvity operating KPIs
KPILatestPeriodChange on a yearRecent periods
Reconciliati on of financial organic revenue growth from continuing operations (change on a year)3%quarter to 5 Apr 2026down 1.0 points
Product revenue$596.8Mquarter to 4 Oct 2026up 4.1%
Service revenue$132.1Mquarter to 4 Oct 2026up 5.1%
Life Sciences revenue$379.6Mquarter to 4 Oct 2026up 10.7%
Diagnostics revenue$349.3Mquarter to 4 Oct 2026down 1.9%
United States revenue$1.1Bfiscal year to 28 Dec 2025up 2.6%
China revenue$425.1Mfiscal year to 28 Dec 2025down 5.5%
Americas revenue$341.9Mquarter to 4 Oct 2026up 11.3%
Europe revenue$220.8Mquarter to 4 Oct 2026up 9.1%
Germany revenue$177.7Mfiscal year to 28 Dec 2025up 9.3%
Asia revenue$166.2Mquarter to 4 Oct 2026down 12.2%
United Kingdom revenue$126.8Mfiscal year to 28 Dec 2025up 12.4%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Revvity's revenue in fiscal 2025?

$2.86 billion for fiscal year 2025 (the twelve months to 28 Dec 2025), as reported in its annual report.

What was Revvity's net income in fiscal 2025?

$241 million for fiscal year 2025 (the twelve months to 28 Dec 2025).

What were Revvity's diluted earnings per share in fiscal 2025?

$2.07 for fiscal year 2025 (the twelve months to 28 Dec 2025).

What is Revvity's gross margin?

54.8% for fiscal year 2025 (the twelve months to 28 Dec 2025): gross profit divided by revenue.

What is Revvity's operating margin?

12.5% for fiscal year 2025 (the twelve months to 28 Dec 2025): operating income divided by revenue.

How much free cash flow did Revvity generate in fiscal 2025?

$509 million for fiscal year 2025 (the twelve months to 28 Dec 2025): operating cash flow less capital expenditure.

Where does Revvity's revenue come from?

In fiscal 2025, by segment: Life Sciences $1.43B (50%), Diagnostics $1.42B (50%), out of $2.86B in all, as stated in its annual report.

In the terminal

Twenty years of Revvity's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans